Marijuana - Public Weed Stocks & Analysis

[Cbdpotential]

“With Anavex drug candidates targeting the sigma-1 receptor, and with the mechanism of action being further validated, we are even more encouraged to advance our studies with additional neurodegenerative diseases,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The Company is intrigued to realize the direct link to the body’s endocannabinoid system and to proceed with potential studies with our sigma-1 drugs candidates and cannabinoids.”

http://www.anavex.com/?news=anavex-encouraged-by-scientific-data-confirming-sigma-1-receptors-beneficial-direct-interaction-with-cannabinoid-receptor

http://hdl.handle.net/1957/28916